VR Logo

NanoViricides Inc. (NNVC) download report


Healthcare | Biotechnology & Pharma Research

NanoViricides Inc. (NNVC) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections.

IPO Date: 26-Oct-2005

Exec. Chairman, Pres, CEO & Sec.: Dr. Anil R. Diwan Ph.D.

Chief Financial Officer: Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA

Listing: NYSE: NNVC

Country: United States

Headquarters: Shelton, CT

Website: https://www.nanoviricides.com

Key Facts

Market cap: $22.18 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-8.40 Mln

Cash: $15.57 Mln

Total Debt: $0.16 Mln

Insider's Holding: 5.16%

Liquidity: Low

52 Week range: $1.04 - 7.86

Shares outstanding: 11,554,000

10 Years Aggregate:

  • CFO: $-66.75 Mln
  • EBITDA: $-76.65 Mln
  • Net Profit: $-91.67 Mln

Stock Performance

Time Period NanoViricides (NNVC) S&P BSE Sensex S&P Small-Cap 600
YTD-49.19-9.18-18.78
1 month-12.09-4.78-8.00
3 months-9.57-9.66-13.65
1 Year-59.270.81-17.19
3 Years-26.7110.336.10
5 Years-41.2511.345.87
10 Years-26.1611.749.84
As on 01-Jul-2022
Year NanoViricides (NNVC) S&P Small-Cap 600 S&P BSE Sensex
202129.6225.2721.99
202014.349.5715.75
2019-37.2520.8614.38
2018-77.09-9.705.87
2017-17.7511.7327.91
2016-9.3224.741.95
2015-56.62-3.36-5.03